About Company
Alkeus Pharmaceuticals Inc. is a biopharmaceutical company dedicated to developing innovative therapies for serious retinal diseases with significant unmet needs.
Founded in 2010 and headquartered in Cambridge, Massachusetts, Alkeus Pharmaceuticals focuses on creating transformative treatments for progressive eye diseases, particularly Stargardt disease and geographic atrophy associated with age-related macular degeneration (AMD). The company's lead candidate, gildeuretinol (ALK-001), is an investigational oral therapy designed to reduce retinal damage caused by the dimerization of vitamin A, a key factor in various retinal diseases. Alkeus has received several designations from the FDA, including Breakthrough Therapy and Fast Track designations, highlighting its commitment to addressing critical health challenges in ophthalmology.